US09077B1044 - Common Stock
BIOATLA INC
NASDAQ:BCAB (6/13/2024, 8:09:16 PM)
After market: 1.52 -0.05 (-3.18%)1.57
-0.01 (-0.63%)
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 66 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include BA3011 (Mecbotamab vedotin), BA3021 (Ozuriftabmab vedotin), BA3071 and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder and gastric cancer, and cervical cancer. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
BIOATLA INC
11085 Torreyana Road
San Diego CALIFORNIA 92121
P: 18585580708
CEO: Jay M. Short
Employees: 66
Website: https://www.bioatla.com/
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients...
BCAB stock results show that BioAtla beat analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioAtla (NASDAQ:BCAB) just reported results for the first quarter of 2024.BioAt...
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable...
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BCAB stock results show that BioAtla beat analyst estimates for earnings per share the fourth quarter of 2023.
Here you can normally see the latest stock twits on BCAB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: